Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 11/20 | 0.56 |
| ▸ | EGFR | P00533 | 9/20 | 0.52 |
| ▸ | INSR | P06213 | 2/20 | 0.50 |
| ▸ | IGF1R | P08069 | 2/20 | 0.50 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30105787 | 0.90 | ALK (0.52) | ALKEGFRINSRIGF1RMAP4K1 | |
| SCHEMBL24940740 | 0.90 | ALK (0.52) | ALKEGFRINSRIGF1RMAP4K1 | |
| SCHEMBL30105859 | 0.83 | EGFR (0.54) | ALKEGFRINSRIGF1R | |
| SCHEMBL24940744 | 0.83 | EGFR (0.54) | ALKEGFRINSRIGF1R | |
| SCHEMBL24940998 | 0.82 | ALK (0.64) | ALKEGFRINSRIGF1RMAP4K1 | |
| SCHEMBL24940069 | 0.82 | ALK (0.77) | ALKEGFRINSRIGF1RMAP4K1 | |
| SCHEMBL31498858 | 0.82 | ALK (0.64) | ALKEGFRINSRIGF1RMAP4K1 | |
| SCHEMBL30105847 | 0.82 | ALK (0.77) | ALKEGFRINSRIGF1RMAP4K1 | |
| SCHEMBL24940907 | 0.82 | EGFR (0.55) | ALKEGFRINSRIGF1RMAP4K1 | |
| SCHEMBL30105960 | 0.82 | EGFR (0.55) | ALKEGFRINSRIGF1RMAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101052-A1 | COMPOUND FOR EGFR KINASE INHIBITOR, COMPOSITION, AND USE THEREOF | INNOVATION INSTITUTE FOR ARTIFICIAL INTELLIGENCE IN MEDICINE OF ZHEJIANG UNIVERSITY (CN) | 2025-03-27 | — | — | US | disclosed |
| WO-2023006088-A1 | COMPOUND FOR EGFR KINASE INHIBITOR, COMPOSITION AND USE THEREOF | 浙江大学智能创新药物研究院 | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101052-A1 | COMPOUND FOR EGFR KINASE INHIBITOR, COMPOSITION, AND USE THEREOF | EGFR, ERBB2, ERBB3 | ALK 68/4885EGFR 1/4885INSR 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.